Survey and Recommendations on the Use of P-Values Driving Decisions in Nonclinical Pharmaceutical Applications

References

• Altan, S., Geys, H., Kuhn, M., LeBlond, D., and Peterson, J. (2018), Nonclinical Statistics. Hoboken, NJ: Wiley StatsRef: Statistics Reference Online, available at DOI: 10.1002/9781118445112.stat08058.
   Google Scholar
• Altan, S., Kolassa, J., and Novick, S. (2021), “Report on the Non-Clinical Biostatistics Scientific Working Group on P-Values,” Biopharm Report, 28, 10–12.
   Google Scholar
• Amaratunga, D. (n.d.), “Practical Matters Regarding p-Values and the Generalizability of Results,” Unpublished Manuscript.
   Google Scholar
• Benjamin, D., and Berger, J. (2019), “Three Recommendations for Improving the Use of p-Values,” The American Statistician, 73, 186–191. DOI: 10.1080/00031305.2018.1543135.
   Web of Science ®Google Scholar
• Billheimer, D. (2019), “Predictive Inference and Scientific Reproducibility,” The American Statistician, 73(S1), 291–295. DOI: 10.1080/00031305.2018.1518270.
   Google Scholar
• Blume, J., Greevy, R., Welty, V., Smith, J., and Dupont, W. (2019), “An Introduction to Second-Generation p-Values,” The American Statistician, 73(S1), 157–167. DOI: 10.1080/00031305.2018.1537893.
   Google Scholar
• Boos, D. D., and Stefanski, L. A. (2011), “P-Value Precision and Reproducibility,” The American Statistician, 65, 213–221. DOI: 10.1198/tas.2011.10129.
   PubMed Web of Science ®Google Scholar
• Carroll, A. (2016), “Undue Influence: The P Value in Scientific Publishing and Health Policy,” JAMA Health Forum, DOI: 10.1001/jamahealthforum.2016.0026.
   Google Scholar
• Editorial in Nature. (2019), “It’s Time to Talk About Ditching Statistical Significance,” Nature, 567, 283.
   Web of Science ®Google Scholar
• FDA. (2001), Draft Guidance for Industry: Statistical Aspects of the Design, Analysis, and Interpretation of Chronic Rodent Carcinogenicity Studies of the Pharmaceuticals. MD: Center for Drug Evaluation and Research (CDER).
   Google Scholar
• Gadbury, G. L., and Allison, D. B. (2012), “Inappropriate Fiddling with Statistical Analyses to Obtain a Desirable P-Value: Tests to Detect Its Presence in Published Literature,” PLOS One, 7, e46363. DOI: 10.1371/journal.pone.0046363.
   PubMed Web of Science ®Google Scholar
• Gibson, E. W. (2021), “The Role of p-Values in Judging the Strength of Evidence and Realistic Replication Expectations. Special Section on Roles of Hypothesis Testing, p-Values, and Decision-Making in Biopharmaceutical Research,” Statistics in Biopharmaceutical Research, 13, 6–18. DOI: 10.1080/19466315.2020.1724560.
   Web of Science ®Google Scholar
• Goodman, S. N. (1992), “A Comment on Replication, p-Values and Evidence,” Statistics in Medicine, 11, 875–879. DOI: 10.1002/sim.4780110705.
   PubMed Web of Science ®Google Scholar
• Hamasaki, T., Bretz, F., LaVange, L. M., Müller, P., Pennello, G., and Pinheiro, J. C. (2021), “Editorial: Roles of Hypothesis Testing, p-Values and Decision Making in Biopharmaceutical Research. Special Section on Roles of Hypothesis Testing, p-Values, and Decision-Making in Biopharmaceutical Research,” Statistics in Biopharmaceutical Research, 13, 1–5. DOI: 10.1080/19466315.2021.1874803.
   Web of Science ®Google Scholar
• Harrington, D., D’Agostino, R. B., Gatsonis, C., Hogan, J. W., Hunter, D. J., Normand, S.-L. T., Drazen, J. M., and Hamel, M. B. (2019), “New Guidelines for Statistical Reporting in the Journal,” The New England Journal of Medicine, 381, 285–286. DOI: 10.1056/NEJMe1906559.
   PubMed Web of Science ®Google Scholar
• Jeffreys, H. (1961), Theory of Probability, Oxford: Oxford University Press.
   Google Scholar
• Kraemer, H. C. (2019), “Is It Time to Ban the P Value,” JAMA Psychiatry, 76, 1219–1220. DOI: 10.1001/jamapsychiatry.2019.1965.
   PubMed Web of Science ®Google Scholar
• McShane, B., Gal, D., Gelman, A., Robert, C., and Tackett, J. (2019), “Abandon Statistical Significance,” The American Statistician, 73, 235–245. DOI: 10.1080/00031305.2018.1527253.
   Web of Science ®Google Scholar
• National Academies of Sciences, Engineering, and Medicine. (2019), Reproducibility and Replicability in Science. Washington, DC: The National Academies Press, available at DOI: 10.17226/25303.
   Google Scholar
• Pearson, K. (1900), “On the Criterion that a Given System of Deviations from the Probable in the Case of a Correlated System of Variables is such that it can be Reasonably Supposed to Have Arisen from Random Sampling,” The London, Edinburgh, and Dublin Philosophical Magazine and Journal of Science?, 50, 157–175. DOI: 10.1080/14786440009463897.
   Google Scholar
• Wasserstein, R. L., and Lazar, N. A. (2016), “The ASA Statement on p-Values: Context, Process, and Purpose,” The American Statistician, 70, 129–133. DOI: 10.1080/00031305.2016.1154108.
   Web of Science ®Google Scholar
• Wasserstein, R. L., Schirm, A. L., and Lazar, N. A. (2019), “Moving to a World Beyond,” The American Statistician, 73(S1), 1–1. p < 0.05,”
   Google Scholar
• Trafimow, D., and Marks, M. (2015), “Editorial,” Basic and Applied Social Psychology, 37, 1–2. DOI: 10.1080/01973533.2015.1012991.
   Web of Science ®Google Scholar

References for Drug Discovery/-omics section

• Aban, I., and George, B. (2015), “Statistical Considerations for Preclinical Studies,” Experimental Neurology, 270, 82–87. DOI: 10.1016/j.expneurol.2015.02.024.
   PubMed Web of Science ®Google Scholar
• Akaike, H. (1974), “A New Look at the Statistical Model Identification,” IEEE Transactions on Automatic Control, 19, 716–723. DOI: 10.1109/TAC.1974.1100705.
   Web of Science ®Google Scholar
• Begley, C., and Ellis, L. (2012), “Drug Development: Raise Standards for Preclinical Cancer Research,” Nature, 483, 531–533. DOI: 10.1038/483531a.
   PubMed Web of Science ®Google Scholar
• Benjamini, Y., and Hochberg, Y. (1995), “Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing,” Journal of the Royal Statistical Society, Series B, 57, 289–300. http://www.jstor.org/stable/2346101 DOI: 10.1111/j.2517-6161.1995.tb02031.x.
   Web of Science ®Google Scholar
• Benjamini, Y. (2016), “It’s Not the p-values’ Fault,” Supplemental material to Wasserstein and Lazar (2016).
   Google Scholar
• Border, R., Johnson, E. C., Evans, L. M., Smolen, A., Berley, N., Sullivan, P. F., and Keller, M. C. (2019), “No Support for Historical Candidate Gene or Candidate Gene-by-Interaction Hypotheses for Major Depression Across Multiple Large Samples,” The American Journal of Psychiatry, 176, 376–387. DOI: 10.1176/appi.ajp.2018.18070881.
   PubMed Web of Science ®Google Scholar
• Checkley, S., MacCallum, L., Yates, J., Jasper, P., Luo, H., Tolsma, J., and Bendtsen, C. (2015), “Bridging the Gap Between in Vitro and in Vivo: Dose and Schedule Predictions for the ATR Inhibitor AZD6738,” Scientific Reports, 5, 13545 DOI: 10.1038/srep13545.
   PubMed Web of Science ®Google Scholar
• Edwards, D., and Berry, J. J. (1987), “The Efficiency of Simulation-Based Multiple Comparisons,” Biometrics, 43, 913–928. DOI: 10.2307/2531545.
   PubMed Web of Science ®Google Scholar
• Goodman, S. (2008), “A Dirty Dozen: Twelve p-Value Misconceptions,” Seminars in Hematology, 45, 135–140. DOI: 10.1053/j.seminhematol.2008.04.003.
   PubMed Web of Science ®Google Scholar
• Greenland, S. (2019), “Valid P-Values Behave Exactly as They Should: Some Misleading Criticisms of P-Values and Their Resolution With S-Values,” The American Statistician, 73, 106–114. DOI: 10.1080/00031305.2018.1529625.
   Web of Science ®Google Scholar
• Hwang, T., Carpenter, D., Lauffenburger, J., Wang, B., Franklin, J. M., and Kesselheim, A. (2016), “Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results,” JAMA Internal Medicine, 176, 1826–1833. DOI: 10.1001/jamainternmed.2016.6008.
   PubMed Web of Science ®Google Scholar
• Kraljevic, S., Stambrook, P., and Pavelic, K. (2004), “Accelerating Drug Discovery,” EMBO Reports, 5, 837–842. DOI: 10.1038/sj.embor.7400236.
   PubMed Web of Science ®Google Scholar
• Lendrem, D. (2002), “Statistical Support to Non-Clinical,” Pharmaceutical Statistics, 1, 71–73. DOI: 10.1002/pst.29.
   Google Scholar
• Polak, S. (2013), “In Vitro to Human in Vivo Translation—Pharmacokinetics and Pharmacodynamics of Quinidine,” Altex, 30, 309–318. DOI: 10.14573/altex.2013.3.309.
   PubMedGoogle Scholar
• Prinz, F., Schlange, T., and Asadullah, K. (2011), “Believe It or Not: How Much Can We Rely on Published Data on Potential Drug Targets?,” Nature Reviews. Drug Discovery, 10, 712. DOI: 10.1038/nrd3439-c1.
   PubMed Web of Science ®Google Scholar
• Quintana, D., and Williams, D. (2018), “Bayesian Alternatives for Common Null-Hypothesis Significance Tests in Psychiatry: A Non-Technical Guide Using JASP,” BMC Psychiatry, 18, 178. DOI: 10.1186/s12888-018-1761-4.
   PubMed Web of Science ®Google Scholar
• Storey, J. D., and Tibshirani, R. (2003), “Statistical Significance for Genomewide Studies,” Proceedings of the National Academy of Sciences of the United States of America, 100, 9440–9445. DOI: 10.1073/pnas.1530509100.
   PubMed Web of Science ®Google Scholar
• Tukey, J. (1962), “The Future of Data Analysis,” The Annals of Mathematical Statistics, 33, 1–67. DOI: 10.1214/aoms/1177704711.
   Google Scholar
• Tukey, J. (1980), “We Need Both Exploratory and Confirmatory,” The American Statistician, 34, 23–25.
   Web of Science ®Google Scholar
• Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., Li, B., Madabhushi, A., Shah, P., Spitzer, M., and Zhao, S. (2019), “Applications of Machine Learning in Drug Discovery and Development,” Nat Rev Drug Discov, 18, 463–477. DOI: 10.1038/s41573-019-0024-5.
   PubMed Web of Science ®Google Scholar
• Wiklund, S. (2019), “A Modelling Framework for Improved Design and Decision-Making in Drug Development,” PLos One, 14, e0220812. DOI: 10.1371/journal.pone.0220812.
   PubMed Web of Science ®Google Scholar

References to Preclinical Safety/Toxicology Section

• Altman, D. G., and Bland, J. M. (1995), “Statistics Notes: Absence of Evidence is Not Evidence of Absence,” BMJ, 311, 485–485. DOI: 10.1136/bmj.311.7003.485.
   PubMed Web of Science ®Google Scholar
• Bailer, A., and Portier, C. (1988), “Effects of Treatment-Induced Mortality and Tumor-Induced Mortality on Tests for Carcinogenicity in Small Samples,” Biometrics, 44, 417–431. DOI: 10.2307/2531856.
   PubMed Web of Science ®Google Scholar
• Benjamini, Y., and Hochberg, Y. (1995), “Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing,” Journal of the Royal Statistical Society, Series B, 1, 289–300. DOI: 10.1111/j.2517-6161.1995.tb02031.x.
   Google Scholar
• Bieler, G., and Williams, R. (1993), “Ratio Estimates, the Delta Method, and Quantal Response Tests for Increased Carcinogenicity,” Biometrics, 49, 793–801. DOI: 10.2307/2532200.
   PubMed Web of Science ®Google Scholar
• DaSilva, J., Cobbina, E., Tyszkiewicz, C., Li, D., and Goody, S. (2019), “Quantitative Association Analyses of CNS Safety Pharmacology Parameters to Clinical Observations in Toxicology Studies,” Journal of Pharmacological and Toxicological Methods, 9, 106595. DOI: 10.1016/j.vascn.2019.05.002.
   Google Scholar
• Gregg, D. (1994), “A Comparison of Tumour Incidence Analyses Applicable in Single-Sacrifice Animal Experiments,” Statistics in Medicine, 3, 689–708.
   Google Scholar
• Dunnett, C. (1955), “A Multiple Comparison Procedure for Comparing Several Treatments with a Control,” Journal of the American Statistical Association, 12, 1096–1121. DOI: 10.1080/01621459.1955.10501294.
   Google Scholar
• EFSA (2019), Technical Report, Outcome of the Pesticides Peer Review Meeting on General Recurring Issues in Ecotoxicology.
   Google Scholar
• EPA (2010), “National Pollutant Discharge Elimination System Test of Significant Toxicity Implementation Document,” Environmental Protection Agency Office of Wastewater Management, 6, 5–7.
   Google Scholar
• EPA (2012), Benchmark Dose Technical Guidance, EPA/100/R-12/001
   Google Scholar
• Guy, R. C. (2014), Ames Test, Editor(s): Philip Wexler Encyclopedia of Toxicology (3rd ed., pp. 187–188), Waltham, MA: Academic Press.
   Google Scholar
• Hothorn, L. (2014), “Statistical Evaluation of Toxicological Bioassays – A Review,” Toxicology Research, 3, 418–432. DOI: 10.1039/C4TX00047A.
   Web of Science ®Google Scholar
• Hothorn, L., and Hasler, M. (2008), “Proof of Hazard and Proof of Safety in Toxicological Studies Using Simultaneous Confidence Intervals for Differences and Ratios to Control,” Journal of Biopharmaceutical Statistics, 18, 915–933. DOI: 10.1080/10543400802287511.
   PubMed Web of Science ®Google Scholar
• Kluxen, F., and Hothorn, L. (2020), “Alternatives to Statistical Decision Trees in Regulatory (Eco-)Toxicological Bioassays,” Archives of Toxicology, 3, 19. DOI: 10.1007/s00204-020-02690-w.
   Google Scholar
• Lazic, S., Semenova, E., and Williams, D. (2020), “Determining Organ Weight Toxicity with Bayesian Causal Models: Improving on the Analysis of Relative Organ Weights,” Scientific Reports, 6625. DOI: 10.1038/s41598-020-63465-y.
   PubMed Web of Science ®Google Scholar
• Lazic, S., Edmunds, N., and Pollard, C. (2018), “Predicting Drug Safety and Communicating Risk: Benefits of a Bayesian Approach,” Toxicological Sciences: An Official Journal of the Society of Toxicology, 162, 89–98. DOI: 10.1093/toxsci/kfx236.
   PubMed Web of Science ®Google Scholar
• MacGregor, J., Frötschl, R., White, P., Crump, K., Eastmond, D., Fukushima, S., Guérard, M., Fukushima, S., Guérard, M., Hayashi, M., Soeteman-Hernández, L., Kasamatsu, T., Levy, D., Morital, M., Müller, L., Schoeny, R., Schuler, M., Thybaud, V., and Johnson, G. (2015), “IWGT Report on Quantitative Approaches to Genotoxicity Risk Assessment I. Methods and Metrics for Defining Exposure-Response Relationships and Points of Departure (PoD),” Mutation Research. Genetic Toxicology and Environmental Mutagenesis, 783, 55–65. DOI: 10.1016/j.mrgentox.2014.09.011.
   PubMed Web of Science ®Google Scholar
• Nüesch, P. (1991), Order Restricted Statistical Inference, T. Robertson, F. T. Wright, R. L. Dykstra Wiley Series in Probability and Mathematical Statistics, Wiley, Chichester, 1988. pp. 488. J. Appl. Econ.,
   Google Scholar
• Portier, C. J., and Bailer, A. J. (1989), “Testing for Increased Carcinogenicity Using a Survival-adjusted Quantal Response Test,” Fundamental and Applied Toxicology: Official Journal of the Society of Toxicology, 12, 731–737. DOI: 10.1016/0272-0590(89)90004-3.
   PubMedGoogle Scholar
• Schaarschmidt, F., Sill, M., and Hothorn, L. (2008), “Approximate Simultaneous Confidence Intervals for Multiple Contrasts of Binomial Proportions,” Biometrical Journal, 10, 782–792. DOI: 10.1002/bimj.200710465.
   Google Scholar
• Tarone, R. (1982), “The Use of Historical Control Information in Testing for a Trend in Poisson Means,” Biometrics, 38, 457–462. DOI: 10.2307/2530459.
   PubMed Web of Science ®Google Scholar
• Williams, D., Lazic, S., Foster, A., Semenova, E., and Morgan, P. (2020), “Predicting Drug-Induced Liver Injury with Bayesian Machine Learning,” Chemical Research in Toxicology, 239–248. DOI: 10.1021/acs.chemrestox.9b00264.
   PubMed Web of Science ®Google Scholar

References for CMC Section

A. Parameter Criticality Identification

• Atkinson, A., and Donev, A. (1992), Optimum Experimental Designs. Clarendon Press: Oxford
   Google Scholar
• Box, G., Hunter, W. G., and Hunter, J. S. (2005), Statistics for Experimenters: Design, Innovation, and Discovery (2nd ed.), Hoboken, NJ: Wiley.
   Google Scholar
• Burdick, R. K., Pfahler, L. B., Zhang, L., Quiroz, J., Vukovinsky, K., Leblond, D., and Sidor, L. (2017), Statistical Applications for Chemistry, Manufacturing and Controls (CMC) in the Pharmaceutical Industry, Cham, Switzerland: Springer International Publishing.
   Google Scholar
• Cochran, W. G., and Cox, G. M. (1957), Experimental Designs, New York: Wiley.
   Google Scholar
• Fang, K.-T., Li, R., and Sudjianto, A. (2006), Design and Modeling for Computer Experiments, Boca Raton, FL: Chapman and Hall/CRC, Boca Raton.
   Google Scholar
• Gramacy, R. B. (2020), Surrogates: Gaussian Process Modeling, Design, and Optimization for the Applied Sciences, Boca Raton, FL: Chapman and Hall/CRC.
   Google Scholar
• Hakemeyer, C., McKnight, N., St. John, R., Meier, S., Trexler-Schmidt, M., Kelley, B., Zettl, F., Puskeiler, R., Kleinjans, A., Lim, F., and Wurth, C. (2016), “Process Characterization and Design Space Definition,” Biologicals: Journal of the International Association of Biological Standardization, 44, 306–318. DOI: 10.1016/j.biologicals.2016.06.004.
   PubMed Web of Science ®Google Scholar
• John, J. A., and Quenouille, M. H. (1977), Experiments: Design and Analysis. New York: Macmillan Publishing Co.
   Google Scholar
• Lee, B. W., Peterson, J. J., Yin, K., Stockdale, G. S., Liu, Y. C., and O’Brien, A. (2020), “System Model Development and Computer Experiments for Continuous API Manufacturing,” Chemical Engineering Research and Design, 156, 495–506. DOI: 10.1016/j.cherd.2020.02.003.
   Web of Science ®Google Scholar
• Li, F., Evans, B., Liu, F., Zhang, J., Wang, K., and Cheng, A. (2018), “Removing Subjectivity from the Assessment of Critical Process Parameters and Their Impact,” Pharmaceutical Technology, 42, 46–54.
   Google Scholar
• Otava, M., and Mylona, K. (2020), “Communicating Statistical Conclusions of Experiments to Scientists,” Quality and Reliability Engineering International, 36, 2688–2698. DOI: 10.1002/qre.2697.
   Web of Science ®Google Scholar
• Perry, L. A., Montgomery, D. C., and Fowler, J. W. (2001), “Partition Experimental Designs for Sequential Processes: Part I—First-Order Models,” Quality and Reliability Engineering International, 17, 429–443.
   Web of Science ®Google Scholar
• Plackett, R. L., and Burman, J. P. (1946), “The Design of Optimum Multifactorial Experiments,” Biometrika, 33, 305–325. DOI: 10.1093/biomet/33.4.305.
   Web of Science ®Google Scholar
• Santer, T. J., Williams, B. J., and Notz, W. I. (2003), The Design and Analysis of Computer Experiments, New York: Springer.
   Google Scholar
• Wang, K., Ide, N. D., Dirat, O., Subashi, A. K., Thomson, N. K., Vukovinsky, K. E., and Watson, T. J. (2016), “Statistical Tools to Aid the Assessment of Critical Process Parameters,” Pharmaceutical Technology, 40, 36–44.
   Google Scholar

B. Quality by Design

• Dispas, A., Avohou, H. T., Lebrun, P., Hubert, P., and Hubert, C. (2018), “‘Quality by Design’ Approach for the Analysis of Impurities in Pharmaceutical Drug Products and Drug Substances, TrAC Trends in Analytical Chemistry, 101, 24–33. DOI: 10.1016/j.trac.2017.10.028.
   Web of Science ®Google Scholar
• LeBrun, P., Boulanger, B., Debrus, B., Lambert, P., and Hubert, P. (2013), “A Bayesian Design Space for Analytical Methods Based on Multivariate Models and Predictions,” Journal of Biopharmaceutical Statistics, 23, 1330–1351. DOI: 10.1080/10543406.2013.834922.
   PubMed Web of Science ®Google Scholar
• Peterson, J. J. (2007), A Review of Bayesian Reliability Approaches to Multiple Response Surface Optimization. Chapter 10 in Bayesian Process Monitoring, Control, and Optimization, Colosimo, B. M. and Del Castillo, E., eds., New York: Chapman and Hall/CRC.
   Google Scholar
• Peterson, J. J. (2008), “A Bayesian Approach to the ICH Q8 Definition of Design Space,” Journal of Biopharmaceutical Statistics, 18, 959–975.
   PubMed Web of Science ®Google Scholar
• Peterson, J. J., and Yahyah, M. (2009), “A Bayesian Design Space Approach to Robustness and System Suitability for Pharmaceutical Assays and Other Processes,” Statistics in Biopharmaceutical Research, 1, 441–449. DOI: 10.1198/sbr.2009.0037.
   Web of Science ®Google Scholar
• Peterson, J. J., and Lief, K. (2010), “The ICH Q8 Definition of Design Space: A Comparison of the Overlapping Means and the Bayesian Predictive Approaches,” Statistics in Biopharmaceutical Research, 2, 249–259. DOI: 10.1198/sbr.2009.08065.
   Web of Science ®Google Scholar
• Peterson, J. J. (2020), Process Development and Validation, Chapter 19 in Bayesian Methods in Pharmaceutical Research. Lasaffre, W., Baio, G., Boulanger, B., eds., New York: CRC Press.
   Google Scholar
• Scherder, T., and Giacoletti, K. (2020), Bayesian Statistics for Manufacturing, Chapter 24 in Bayesian Methods in Pharmaceutical Research (1st ed.). Lesaffre, E., Baio, G., & Boulanger, B., eds., New York: CRC Press.
   Google Scholar
• Berger, R., and Hsu, J. (1996), “Bioequivalence Trials, Intersection-Union Tests and Equivalence Confidence Intervals,” Statistical Science, 11, 283–319. DOI: 10.1214/ss/1032280304.
   Web of Science ®Google Scholar
• European Pharmacopoeia 6.0, General Chapter 5.3. Statistical Analysis of Results of Biological Assays and Tests, 01/2008:50300.
   Google Scholar
• Faya, P., Rauk, A. P., Griffiths, K. L., and Parekh, B. (2020), “A Curve Similarity Approach to Parallelism Testing in Bioassay,” Journal of Biopharmaceutical Statistics, 30, 721–733. DOI: 10.1080/10543406.2020.1730875.
   PubMed Web of Science ®Google Scholar
• Hauk, W. W., Capen, R. C., Callahan, J. D., De Muth, J. E., Hsu, H., Lansky, D., Sajjadi, N. C., Seaver, S. S., Singer, R. R., and Weisman, D. (2005), “Assessing Parallelism Prior to Determining Relative Potency,” PDA J. Pharmaceutical Science & Technology, 59, 127–137.
   PubMedGoogle Scholar
• Schofield, T. L. (2015), Nonclinical for Pharmaceutical and Biotechnology Industries, Chapter 17 in Lifecycle Approach to Bioassays. Zhang, L., Altan, S., eds., Springer, Cham: CRC Press.
   Google Scholar
• Schuirmann, D. (1987), “A Comparison of the Two One-Sided Tests Procedure and the Power Approach for Assessing the Equivalence of Average Bioavailability,” Journal of Pharmacokinetics and Biopharmaceutics, 15, 657–680. DOI: 10.1007/BF01068419.
   PubMedGoogle Scholar
• USP General Chapter <1032 > Design and Development of Biological Assays.
   Google Scholar
• Yang, H. (2020), Emerging Non-Clinical Biostatistics in Biopharmaceutical Development and Manufacturing, New York: Chapman and Hall/CRC Press.
   Google Scholar

D. Stability

• Altan, S., Manola, A., Shoung, J., and Shen, Y. (2013), “Perspectives on Pooling as Described in the ICH Q1E Guidance,” In JSM Proceedings, Biopharm Section. (pp. 1490–1496), Alexandria, VA: American Statistical Association.
   Google Scholar
• Avohou, T. H., Lebrun, P., Rozet, E., and Boulanger, B. (2020), Bayesian Methods for the Design and Analysis of Stability Studies, Chapter 21 in Bayesian Methods in Pharmaceutical Research Lasaffre, w, Baio, G, Boulanger, B, eds. (2020), New York: CRC Press.
   Google Scholar
• Bancroft, T. A. (1964), “Analysis and Inference for Incompletely Specified Models Including the Use of Preliminary Tests of Significance,” Biometrics, 20, 427–442. DOI: 10.2307/2528486.
   Web of Science ®Google Scholar
• Burdick, R., LeBlond, D., Pfahler, L., Quiroz, J., Sidor, L., Vukovinsky, K., and Zhang, L. (2017), Stability Chapter 8 in Statistical Applications for Chemistry, Manufacturing and Controls (CMC) in the Pharmaceutical Industry.
   Google Scholar
• Carlin, B. P., and Louis, T. A. (2009), Bayesian Methods for Data Analysis. Boca Raton, FL: CRC Press.
   Google Scholar
• Chen, J. J., Hwang, J. S., and Tsong, Y. (1995), “Estimation of the Shelf-Life of Drugs with Mixed Effects Models,” Journal of Biopharmaceutical Statistics, 5, 131–140. DOI: 10.1080/10543409508835102.
   PubMedGoogle Scholar
• Chow, S. C., and Shao, J. (1991), “Estimating Drug Shelf-Life with Random Batches,” Biometrics, 47, 1071–1079. DOI: 10.2307/2532659.
   PubMed Web of Science ®Google Scholar
• International Conference on Harmonization (2003), Evaluation for Stability Data Q1E, available at http://www.ich.org/fileadmin/Public_Web_Site/CH_Products/Guidelines/Quality/Q1E/Step4/Q1E_Guideline.pdf
   Google Scholar
• Stroup, W. W., and Quinlan, M. (2016), “Statistical Considerations for Stability and the Estimation of Shelf Life,” Chapter 22 in Nonclinical Statistics for Pharmaceutical and Biotechnology Industries, Zhang, L., Kuhn, M., Peers, I. and Altan, S., eds., New York: Springer.
   Google Scholar